8-K

                      SECURITIES AND EXCHANGE COMMISSION

                             Washington, DC 20549

                           ------------------------

                                   FORM 8-K

                                Current Report

                    Pursuant To Section 13 or 15(d) of the

                        Securities Exchange Act of 1934

      Date of Report (date of earliest event reported): October 15, 2002


                                 E-Z-EM, INC.
            (Exact Name of Registrant as Specified in its Charter)

                                   Delaware
                (State or Other Jurisdiction of Incorporation)

                  1-11479                     11-1999504
          (Commission File Number) (IRS Employer Identification No.)


                   717 Main Street, Westbury, New York 11590
         (Address of Principal Executive Offices, Including Zip Code)


                                (516) 333-8230
             (Registrant's Telephone Number, Including Area Code)


ITEM 5.  OTHER EVENTS

         On October 15, 2002, E-Z-EM, Inc., a Delaware corporation (the
         "Company"), issued a press release announcing that the Company's
         stockholders had approved the previously announced merger of a wholly
         owned subsidiary of the Company with and into the Company pursuant to
         which each outstanding share of the Company's Class A common stock
         and each outstanding share of the Company's Class B common stock will
         be converted into one share of a single, newly created class of
         common stock of the Company.

         A copy of the press release is attached hereto as Exhibit 99.1 and is
         hereby incorporated by reference.

ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

         (c) Exhibits

         Exhibit 99.1      Press Release dated October 15, 2002.




                                  SIGNATURES:

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: October 15, 2002                     E-Z-EM, INC.
                                            (Registrant)



                                            By:  /s/ Anthony A. Lombardo
                                                 Anthony A. Lombardo
                                                 President and
                                                 Chief Executive Officer

EX-99

                                                                  Exhibit 99.1

- ------------------------  ----------------------------------------------------

FOR IMMEDIATE RELEASE      CONTACT:  Dennis J. Curtin
                           Senior Vice President - Chief Financial Officer
                           Telephone: (516) 333-8230, Ext. 320
                           Email: dcurtin@ezem.com
- -------------------------  ---------------------------------------------------

              E-Z-EM STOCKHOLDERS APPROVE RECAPITALIZATION MERGER

Westbury, New York, October 15, 2002 - E-Z-EM, Inc. (AMEX: EZM.A/EZM.B)
("E-Z-EM" or the "Company") today announced that stockholders had approved the
previously announced plan to combine the Company's two currently outstanding
classes of common stock - Class A (AMEX: EZM.A) and Class B (AMEX: EZM.B) -
into a single class of common stock (AMEX: EZM).

As provided in the recapitalization merger agreement executed on July 25, 2002
by E-Z-EM, the proposed transaction will be effected by merging a newly formed
subsidiary into E-Z-EM, with E-Z-EM continuing as the surviving corporation in
the merger. As a result of this merger, each outstanding Class A share and
each outstanding Class B share will be converted into one share of a newly
created class of common stock of the Company. Following the transaction, there
will be no super-majority voting requirements applicable to the Company's new
class of common stock in the Company's certificate of incorporation, each
holder will have one vote per share and all matters brought before the
stockholders of the Company, other than the removal of directors, will be
determined by a majority vote. E-Z-EM expects the proposed transaction to be
tax-free to the Company and the holders of the Company's Class A and Class B
shares. The recapitalization merger is expected to be completed in the next
few days, subject to final approval of the listing of the Company's new common
stock on the American Stock Exchange.

About E-Z-EM, Inc.
E-Z-EM, the world's largest manufacturer of contrast agents for
gastrointestinal radiology, has developed the only CT injector on the market
that can help detect contrast extravasation, the new EmpowerCT(TM) with
patented EDA(TM) technology. The Company has also recently introduced a
complete tool kit for virtual colonoscopy (also referred to as CT
colonography, or CTC), an innovative technology that could lead to a
substantial increase in the number of patients being screened for colorectal
cancer. Virtual colonoscopy visualizes the gastrointestinal tract using
advanced CT imaging and 3D computer reconstruction of that data. The Company's
product line consists of the InnerviewGI(TM) 3D imaging workstation; LoSo
Prep(TM) and NutraPrep(TM) patient-friendly colon preparation products and
nutritional meal kits; a tagging agent trade-named Tagitol(TM) to help
practitioners distinguish pathology from colonic residue; and the
PROTOCO2L(TM) carbon dioxide colon insufflation system. E-Z-EM's wholly owned
subsidiary, AngioDynamics, manufactures a wide range of products, including
angiographic, vascular access, thrombolytic, angioplasty, stents, as well as
abdominal infection drainage products. AngioDynamics' focus is on diagnostic
and therapeutic products for interventional radiology and other areas of
minimally invasive surgery. Enteric Products, Inc., another subsidiary,
develops, manufactures and markets tests for detection of the ulcer- and
cancer-causing bacterium Helicobacter pylori. For additional information,
please contact Dennis J. Curtin, Senior Vice President - Chief Financial
Officer, at (516) 333-8230, Ext. 320 (Email: dcurtin@ezem.com) or visit our
corporate web site at www.ezem.com.

                                  * * * * *

The statements made in this document contain certain forward-looking
statements that involve a number of risks and uncertainties. Words such as
"expects", "intends", "anticipates", "plans", "believes", "seeks",
"estimates," or variations of such words and similar expressions, are intended
to identify such forward-looking statements. Investors are cautioned that
actual events or results may differ from the Company's expectations. In
addition to the matters described above, the ability of the Company to develop
its products, future actions by the FDA or other regulatory agencies, results
of pending or future clinical trials, overall economic conditions, general
market conditions, foreign currency exchange rate fluctuations, the effects on
pricing from Group Purchasing Organizations, competition, including
alternative procedures which continue to replace traditional fluoroscopic
procedures, as well as the risk factors listed from time to time in the SEC
filings of E-Z-EM, Inc., including but not limited to its Form 10-K for the
year ended June 1, 2002, may affect the actual results achieved by the
Company. There are also a number of uncertainties, risks, conditions and other
factors which could prevent the implementation of the above described
transaction.